院内感染型メチシリン耐性黄色ブドウ球菌（HA-MRSA）は、病院環境で感染します。症状は、触ると温かいこと、発熱、腫れや痛みを伴う赤いぶつぶつなどです。危険因子としては、入院していること、侵襲的な医療機器を使用していること、長期介護施設に居住していることなどが挙げられます。これは、抗生物質と衛生手順を守ることで予防することができます。
目次
Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Overview
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Companies Involved in Therapeutics Development
Cesa Alliance SA
Destiny Pharma Plc
MGB Biopharma Ltd
Sichuan Saizhuo Pharmaceutical Co Ltd
Techulon Inc (Inactive)
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Drug Profiles
AB-1 - Drug Profile
Product Description
Mechanism Of Action
Antisense Oligonucleotide for Hospital Acquired MRSA - Drug Profile
Product Description
Mechanism Of Action
exeporfinium chloride - Drug Profile
Product Description
Mechanism Of Action
litazolid - Drug Profile
Product Description
Mechanism Of Action
MGBBP-3 - Drug Profile
Product Description
Mechanism Of Action
Peptides to Disrupt Cell Membrane for Infectious Diseases - Drug Profile
Product Description
Mechanism Of Action
Polymer for Community-Acquired and Hospital-Acquired MRSA Infections - Drug Profile
Product Description
Mechanism Of Action
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Dormant Projects
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Discontinued Products
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Product Development Milestones
Featured News & Press Releases
Mar 22, 2018: Sichuan Saizhuo Pharmaceutical obtained the clinical approval for a new drug "Ristazolone Dry Suspension"
Jun 02, 2015: MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by Cesa Alliance SA, 2022
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by Destiny Pharma Plc, 2022
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by MGB Biopharma Ltd, 2022
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by Sichuan Saizhuo Pharmaceutical Co Ltd, 2022
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by Techulon Inc (Inactive), 2022
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Dormant Projects, 2022
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Discontinued Products, 2022
List of Figures
Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
